轉移性癌症治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、癌症類型、最終用戶、地區和競爭格局分類，2021-2031年

全球轉移性癌症治療市場預計將從 2025 年的 801.3 億美元大幅成長至 2031 年的 1,235.3 億美元，複合年成長率為 7.48%。

這些特效藥物旨在延緩癌症進展，延長已從原發部位轉移至遠端部位患者的存活期。這一成長主要受全球晚期癌症發病率上升和基因組分析技術廣泛應用的推動，後者使得標靶治療治療和免疫療法的應用至關重要。例如，美國癌症協會估計，到2025年，美國將新增2,041,910例癌症病例，並有618,120例癌症死亡病例，凸顯了對有效全身治療的迫切需求。儘管需求如此之大，但由於藥物研發高成本以及已通過核准治療方法價格高昂，市場仍面臨巨大的挑戰。這種經濟障礙導致了嚴格的報銷政策，限制了患者的用藥途徑，並加重了醫療預算的壓力，從而阻礙了市場滲透。此外，針對複雜轉移性疾病的安全性和有效性，嚴格的監管要求可能會延長核准時間，迫使製藥公司克服這些經濟和監管障礙才能成功商業化。

市場促進因素

市場擴張的主要驅動力是全球轉移性腫瘤發生率的不斷上升，這導致需要全身性治療的患者數量顯著增加。隨著預期壽命的延長和生活方式相關風​​險因素的增加，已開發國家和新興國家晚期癌症的負擔都在加重，因此需要持續供應先進療法來控制轉移性疾病。 2024年2月，世界衛生組織（WHO）預測，到2050年，全球癌症負擔將激增，新增癌症病例將超過3,500萬例。這比2022年的水平成長了77%，並且與更多患者發展到轉移階段直接相關，從而鞏固了對癌症藥物治療的長期需求。此外，標靶治療和免疫療法的加速應用正在改變臨床格局，使市場從細胞毒性化學療法轉向更有價值、更精準的治療機制。製藥開發商正在優先研發針對特定分子突變和免疫查核點的藥物，提高了以往難以治療的轉移性癌症患者的存活率。這項創新在監管里程碑中得到了清晰的體現，例如美國FDA在2024年核准了60多種抗癌藥物（其中11種First-in-Class療法）。這項變革的商業性影響巨大，像默克公司的Keytruda這樣臨床上成功的免疫療法在2024年創造了約295億美元的銷售額，凸顯了轉移性疾病有效療法的巨大經濟潛力。

市場挑戰

藥物研發的高昂成本，以及已通過核准療法的高昂價格，是全球轉移性癌症治療市場擴張的主要障礙。這種經濟負擔造成了一個明顯的兩難：臨床創新往往凌駕於經濟可行性之上，直接限制了病人獲得維持生命治療的機會。製藥公司為新藥定價是為了收回其巨額研發投資，而這些定價通常超過了支付方和保險體系設定的閾值。因此，醫療體系優先考慮成本控制，而非即時採用昂貴的新治療方法，這阻礙了市場滲透，導致進行性轉移性癌症適應症的醫療覆蓋範圍被延遲，商業性推廣也進展緩慢。這種經濟負擔給全球醫療生態系統帶來了巨大的壓力，造成了商業性推廣環境的不穩定。美國癌症研究協會（AACR）在2025年預測，到2050年，癌症造成的全球累積經濟損失將達到25.2兆美元。如此巨大的宏觀經濟負擔迫使各國醫療機構實施嚴格的報銷政策，導致核准時間延長，並限制了能夠負擔得起這些治療方法的患者人數。最終，這些經濟障礙阻礙了高價值療法充分發揮其商業性潛力，並減緩了市場成長。

市場趨勢

抗體藥物複合體（ADC）臨床研發管線的快速擴張是關鍵趨勢之一。它從根本上改變了治療模式，引入了標靶治療，可將強效細胞毒性物質直接遞送至表達抗原的細胞，作為廣譜化療的替代方案。這一趨勢的驅動力在於克服轉移性固體癌的多重抗藥性，研發人員正大力投資於新型連接子和有效載荷，以拓寬已用盡標準治療方案患者的治療選擇。隨著療效數據的積累，該治療方法的商業規模正在迅速擴大。例如，Astra Zeneca於2025年2月宣布，其旗艦ADC藥物Enhertu在2024年的總合銷售額將達到37.5億美元，這反映了其在HER2陽性轉移性適應症中的巨大成功。另一個關鍵趨勢是靶向放射性配體和診療一體化製劑的商業化，這標誌著從傳統生技藥品向核醫學的策略轉變。這種結合診斷和治療同位素的「同步診斷和治療」方法備受關注，因為它能夠將輻射特異性輸送到前列腺癌和神經內分泌癌的轉移病灶，與體外放射治療相比，可最大限度地降低全身毒性。隨著同位素供應鏈的穩定，這一趨勢的經濟影響將是巨大的。根據諾華公司2025年2月發布的年度報告，其標靶放射性配體療法Pluvicto全年的銷售額達到13.9億美元，凸顯了精準核醫療法在晚期癌症患者治療領域的龐大市場價值。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：轉移性癌症治療藥物的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（化療、免疫療法、荷爾蒙療法、標靶治療、其他）
  • 癌症類型（乳癌、肺癌、攝護腺癌、惡性黑色素瘤、大腸癌、其他）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美轉移性癌症治療藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲轉移性癌症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區轉移性癌症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲轉移性癌症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲轉移性癌症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球轉移性癌症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly & Co.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen Inc.
• Sanofi SA

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for metastatic cancer drugs is projected to expand significantly, from USD 80.13 billion in 2025 to USD 123.53 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 7.48%. These specialized pharmaceutical agents are designed to manage disease progression and extend the survival of patients with cancers that have spread from their original site to distant areas. This growth is primarily driven by the increasing global incidence of advanced-stage cancers and the growing adoption of genomic profiling, which mandates the use of targeted therapeutics and immunotherapies. For example, the American Cancer Society estimated 2,041,910 new cancer cases and 618,120 cancer deaths in the United States in 2025, highlighting the urgent need for effective systemic treatments. Despite this demand, the market faces significant challenges due to the high costs of drug development and the subsequent high prices of approved therapies. This financial barrier limits patient access and strains healthcare budgets, leading to strict reimbursement policies that hinder market penetration. Additionally, stringent regulatory requirements for demonstrating safety and efficacy in complex metastatic conditions can extend approval timelines, requiring pharmaceutical companies to overcome these economic and regulatory obstacles for successful commercialization.

Market Driver

The primary catalyst for market expansion is the escalating global incidence of metastatic malignancies, which significantly enlarges the patient population requiring systemic treatment. As life expectancy rises and lifestyle-associated risk factors proliferate, the burden of advanced-stage cancer is intensifying across both developed and emerging regions, necessitating a sustained supply of advanced therapeutics to manage disseminated disease. The World Health Organization projected in February 2024 that the global cancer burden would surge, with new cancer cases reaching over 35 million by 2050, a 77% increase from 2022 levels, directly correlating to more patients progressing to metastatic stages and ensuring long-term demand for oncological pharmacotherapy. Furthermore, the accelerated adoption of targeted therapies and immunotherapies is reshaping the clinical landscape, moving the market from cytotoxic chemotherapy towards higher-value precision mechanisms. Pharmaceutical developers are prioritizing agents that target specific molecular alterations and immune checkpoints, offering improved survival outcomes for patients with previously untreatable metastatic profiles. This innovation is evident in regulatory milestones, such as the U.S. FDA's over 60 oncology approvals in 2024, including 11 first-in-class therapeutics. The commercial impact of this shift is profound, with clinically successful immunotherapies like Merck & Co.'s Keytruda generating approximately $29.5 billion in 2024 revenues, underscoring the immense financial scale of effective metastatic interventions.

Market Challenge

The exorbitant cost associated with drug development and the subsequent high pricing of approved therapies acts as a formidable barrier to the expansion of the "Global Metastatic Cancer Drugs Market." This financial burden creates a clear dichotomy where clinical innovation outpaces economic feasibility, directly restricting patient access to life-extending treatments. Pharmaceutical companies price novel agents to recoup substantial research and development investments, resulting in costs that often exceed the thresholds set by payers and insurance frameworks. Consequently, market penetration is hindered as healthcare systems prioritize cost containment over the immediate adoption of expensive new regimens, leading to delayed formulary inclusion and reduced commercial uptake for advanced metastatic indications. This economic strain exerts quantifiable pressure on the global healthcare ecosystem, creating a volatile environment for commercial adoption. The American Association for Cancer Research projected in 2025 that the cumulative global economic cost of cancer is set to reach $25.2 trillion by 2050. This immense macroeconomic burden compels national healthcare bodies to enforce stringent reimbursement policies, which prolongs approval timelines and limits the addressable patient population capable of affording these interventions. Ultimately, these financial hurdles dampen the market's growth velocity by preventing high-value therapeutics from reaching their full commercial potential.

Market Trends

A significant trend is the rapid expansion of Antibody-Drug Conjugate (ADC) clinical pipelines, fundamentally altering the treatment paradigm by replacing broad-spectrum chemotherapy with targeted mechanisms that deliver potent cytotoxins directly to antigen-expressing cells. This trend is driven by the need to overcome multidrug resistance in metastatic solid tumors, prompting developers to invest heavily in novel linkers and payloads that improve the therapeutic window for patients who have exhausted standard options. The commercial scale of this modality is rapidly increasing as efficacy data matures; for instance, AstraZeneca reported in February 2025 that combined global sales of their flagship ADC, Enhertu, reached $3.75 billion in 2024, reflecting massive uptake for HER2-positive metastatic indications. Another key trend is the commercialization of targeted radioligand and theranostic agents, signifying a strategic departure from traditional biologics towards nuclear medicine. This "see and treat" approach, pairing diagnostic isotopes with therapeutic counterparts, is gaining traction for its ability to deliver radiation specifically to metastatic deposits in prostate and neuroendocrine cancers, thereby minimizing systemic toxicity compared to external beam radiation. The financial impact of this trend is substantial as supply chains for isotopes stabilize; Novartis's February 2025 Annual Report showed that the targeted radioligand therapy Pluvicto generated full-year sales of $1.39 billion, confirming the high market value of precision nuclear interventions for advanced patient populations.

Key Market Players

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly & Co.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen Inc.
• Sanofi SA

Report Scope

In this report, the Global Metastatic Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metastatic Cancer Drugs Market, By Therapy Type

• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Targeted Therapy
• Others

Metastatic Cancer Drugs Market, By Type of Cancer

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Melanoma
• Colorectal Cancer
• Others

Metastatic Cancer Drugs Market, By End-User

• Hospitals & Clinics
• Ambulatory Centers
• Other

Metastatic Cancer Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Cancer Drugs Market.

Available Customizations:

Global Metastatic Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metastatic Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others)
  • 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Others)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Centers, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Metastatic Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Type of Cancer
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metastatic Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Type of Cancer
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Metastatic Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Type of Cancer
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Metastatic Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Type of Cancer
      • 6.3.3.2.3. By End-User

7. Europe Metastatic Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Type of Cancer
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metastatic Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Type of Cancer
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Metastatic Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Type of Cancer
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Metastatic Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Type of Cancer
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Metastatic Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Type of Cancer
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Metastatic Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Type of Cancer
      • 7.3.5.2.3. By End-User

8. Asia Pacific Metastatic Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Type of Cancer
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Metastatic Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Type of Cancer
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Metastatic Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Type of Cancer
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Metastatic Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Type of Cancer
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Metastatic Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Type of Cancer
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Metastatic Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Type of Cancer
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Metastatic Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Type of Cancer
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Metastatic Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Type of Cancer
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Metastatic Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Type of Cancer
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Metastatic Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Type of Cancer
      • 9.3.3.2.3. By End-User

10. South America Metastatic Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Type of Cancer
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Metastatic Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Type of Cancer
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Metastatic Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Type of Cancer
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Metastatic Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Type of Cancer
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Metastatic Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. AstraZeneca Plc
• 15.4. Novartis AG
• 15.5. Eli Lilly & Co.
• 15.6. Pfizer Inc.
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Johnson & Johnson
• 15.9. Amgen Inc.
• 15.10. Sanofi SA

16. Strategic Recommendations

17. About Us & Disclaimer